Thermo Fisher Scientific has acquired TREK Diagnostic Systems, a provider of microbiology solutions, including blood culture, microorganism identification and antibiotic susceptibility testing products. The addition of VersaTREK platforms to its microbiology portfolio allows Thermo Fisher to offer automated systems for blood culture and the detection of mycobacteria for the first time. VersaTREK complements the company’s manual blood culture systems, to provide the most comprehensive choice of tests and culture media for use in the diagnosis of sepsis and tuberculosis.
TREK’s other major brand, Sensititre, extends Thermo Fisher’s range of manual susceptibility testing and identification products that provide microbiologists with a range of tools to determine the resistance status of a microorganism. “This acquisition is an important step in our strategy to bring a greater choice of workflow solutions to microbiologists worldwide,” said Thermo Fisher Scientific’s Andrew Carr.